[go: up one dir, main page]

MX2009003755A - Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato. - Google Patents

Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato.

Info

Publication number
MX2009003755A
MX2009003755A MX2009003755A MX2009003755A MX2009003755A MX 2009003755 A MX2009003755 A MX 2009003755A MX 2009003755 A MX2009003755 A MX 2009003755A MX 2009003755 A MX2009003755 A MX 2009003755A MX 2009003755 A MX2009003755 A MX 2009003755A
Authority
MX
Mexico
Prior art keywords
chlorophenyl
hydroxy
ethyl carbamate
novel crystal
crystal
Prior art date
Application number
MX2009003755A
Other languages
English (en)
Inventor
Matthew Peterson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009003755A publication Critical patent/MX2009003755A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

La presente invención se relaciona con un cristal novedoso de (S)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato, composiciones farmacéuticas que comprenden este cristal y métodos para elaborar y utilizar este cristal.
MX2009003755A 2006-10-06 2007-10-05 Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato. MX2009003755A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82839206P 2006-10-06 2006-10-06
PCT/US2007/021502 WO2008045391A2 (en) 2006-10-06 2007-10-05 Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate

Publications (1)

Publication Number Publication Date
MX2009003755A true MX2009003755A (es) 2009-07-10

Family

ID=39283405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003755A MX2009003755A (es) 2006-10-06 2007-10-05 Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato.

Country Status (19)

Country Link
US (1) US7632963B2 (es)
EP (1) EP2076258A4 (es)
JP (1) JP2010505856A (es)
KR (1) KR20090076958A (es)
CN (1) CN101657195A (es)
AU (1) AU2007307029A1 (es)
BR (1) BRPI0718131A2 (es)
CA (1) CA2665573A1 (es)
CO (1) CO6180504A2 (es)
CR (1) CR10764A (es)
EA (1) EA200970355A1 (es)
GT (1) GT200900076A (es)
IL (1) IL198016A0 (es)
MX (1) MX2009003755A (es)
NI (1) NI200900050A (es)
NO (1) NO20091771L (es)
SV (1) SV2009003211A (es)
WO (1) WO2008045391A2 (es)
ZA (1) ZA200903095B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
JP6089045B2 (ja) * 2011-12-27 2017-03-01 バイオ−ファーム ソリューションズ カンパニー リミテッド 痛みの緩和または治療に使用するためのフェニルカルバメート化合物
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
EP4382509A4 (en) * 2021-08-05 2025-08-27 Bio Pharm Solutions Co Ltd CRYSTALLINE FORM OF PHENYLCARBAMATE AND PROCESS FOR ITS PREPARATION
KR102399807B1 (ko) 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO2001019368A1 (fr) * 1999-09-10 2001-03-22 Dainippon Ink And Chemicals, Inc. Preparations a base de derives de quinolinone et procede de fabrication
MXPA03007718A (es) * 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para usarse en la prevencion o tratamiento de trastornos neurodegenerativos.
EE05381B1 (et) * 2001-12-21 2011-02-15 Ortho-McNeil�Pharmaceutical,�Inc. MeetodÁ2-(asendatudÁfenl)-2-hdroksetlkarbamaatideÁvalmistamiseks,ÁselleksÁvajalikudÁvahehendidÁningÁsaadudÁkarbamaatideÁpolmorfsedÁvormid
US7767683B2 (en) * 2003-08-18 2010-08-03 H. Lundbeck A/S Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament
NZ553813A (en) * 2004-09-16 2010-09-30 Janssen Pharmaceutica Nv Use of 2-phenyl-1, 2-ethanediol-(DI) carbamates for treating epileptogenesis and epilepsy
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
CA2665573A1 (en) 2008-04-17
GT200900076A (es) 2010-05-18
EP2076258A2 (en) 2009-07-08
US20080085930A1 (en) 2008-04-10
NI200900050A (es) 2010-02-01
AU2007307029A1 (en) 2008-04-17
CR10764A (es) 2009-09-14
US7632963B2 (en) 2009-12-15
NO20091771L (no) 2009-05-05
WO2008045391A2 (en) 2008-04-17
SV2009003211A (es) 2009-11-24
EP2076258A4 (en) 2011-09-28
CO6180504A2 (es) 2010-07-19
JP2010505856A (ja) 2010-02-25
IL198016A0 (en) 2009-12-24
WO2008045391A3 (en) 2008-06-12
CN101657195A (zh) 2010-02-24
EA200970355A1 (ru) 2009-12-30
KR20090076958A (ko) 2009-07-13
BRPI0718131A2 (pt) 2013-11-05
ZA200903095B (en) 2010-07-28

Similar Documents

Publication Publication Date Title
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
NO20090175L (no) Stabile laquinimod sammensetninger
UA97502C2 (ru) Кристаллическая твердая основа разагилина
WO2008036653A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
ZA200801394B (en) Novel sulphonylpyrroles as inhibitors of HDAC S novel sulphonylpyrroles
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
ECSP088854A (es) Moduladores bencimidazolicos de vr1
ZA200903283B (en) Phenylalkylamino carbamate compositions
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
GB0405033D0 (en) Novel pharmaceutical compositions
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
GB0406378D0 (en) Novel pharmaceutical compositions
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
WO2009100275A3 (en) Compositions and devices
TW200634023A (en) Amide prodrug of gemcitabine, compositions and use thereof
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
MX2009003755A (es) Cristal novedoso de (s)-(+)-2-(2-clorofenil)-2-hidroxietil carbamato.
WO2006078886A3 (en) Compounds and compositions as wnt signaling pathway modulators
TW200738649A (en) Calcilytic compounds
WO2007067784A3 (en) Liposomal compositions
WO2009132119A3 (en) Substituted oxazolidinones
WO2010151852A3 (en) Protease inhibitors, compositions and methods of use
TW200728310A (en) Process for the preparation of ferri-succinylcasein

Legal Events

Date Code Title Description
FG Grant or registration